Induction of <i>MYCN</i>-amplified neuroblastoma differentiation through NMYC suppression using PPAR-γ antagonist

Neuroblastomas are the most common extracranial solid tumors in children and have a unique feature of neuronal differentiation. Peroxisome proliferator-activated receptor (PPAR)-γ is reported to neuroprotective effects addition having antitumor various cancers. Thus, we aimed clarify role PPAR-γ agonist antagonist malignant neuroblastomas, which also possess features. In MYCN-amplified neuroblastoma CHP212 cells, treatment with GW9662 induced growth inhibition dose-dependent manner. addition, changed cell morphology increasing expression differentiation marker tubulin beta 3 (TUBB3) G1 phase arrest apoptosis neuroblastoma. Notably, significantly decreased NMYC, B-cell lymphoma 2 (BCL2) bromodomain-containing protein 4 (BRD4). It implied that BRD4, BCL2 suppression by resulted inhibition, differentiation, induction. our vivo study, cells resultant tumor inhibition. Our results provide deeper understanding mechanisms suggest new therapeutic prevention option for neuroblastomas.